Sclareol is a
natural product initially isolated form Salvia sclarea which possesses immune-regulation and anti-inflammatory activities. However, the anti-osteoarthritic properties of
sclareol have not been investigated. The present study is aimed at evaluating the potential effects of
sclareol in interleukin-1β (IL-1β)-induced rabbit chondrocytes as well as an experimental rabbit
knee osteoarthritis model induced by anterior cruciate ligament transection (ACLT). Cultured rabbit chondrocytes were pretreated with 1, 5 and 10 μg/mL
sclareol for 1 h and followed by stimulation of IL-1β (10 ng/mL) for 24 h. Gene expression of
matrix metalloproteinase-1 (MMP-1), MMP-3, MMP-13, tissue inhibitors of metalloproteinase-1 (TIMP-1),
inducible nitric oxide synthase (iNOS) and
cyclooxygenase (COX)-2 was determined by quantitative real-time polymerase chain reaction (qRT-PCR). MMP-3,
TIMP-1, iNOS and COX-2
proteins were measured by Western blotting.
Enzyme-linked
immunosorbent assay (ELISA) was applied for
nitric oxide (NO) and
prostaglandin E2 (
PGE2) assessment. For the in vivo study, rabbits received six weekly 0.3 mL
sclareol (10 μg/mL)
intra-articular injections in the knees four weeks after ACLT surgery. Cartilage was harvested for measurement of MMP-1, MMP-3, MMP-13,
TIMP-1, iNOS and COX-2 by qRT-PCR, while femoral condyles were used for histological evaluation. The in vitro results we obtained showed that
sclareol inhibited the
MMPs, iNOS and COX-2 expression on
mRNA and
protein levels, while increased the
TIMP-1 expression. And over-production of NO and
PGE2 was also suppressed. For the in vivo study, both qRT-PCR results and histological evaluation confirmed that
sclareol ameliorated cartilage degradation. Hence, we speculated that
sclareol may be an ideal approach for treating
osteoarthritis.